Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 11/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 8/20 | 0.54 |
| ▸ | PPARG | P37231 | 11/20 | 0.52 |
| ▸ | FABP2 | P12104 | 1/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13678669 | 0.92 | PPARA (0.46) | PPARACYP2C19CYP1A2CYP3A4MEN1 | |
| SCHEMBL4527329 | 0.91 | PPARA (0.61) | PPARACYP2C19CYP1A2CYP3A4MEN1 | |
| SCHEMBL987343 | 0.82 | PPARA (0.67) | PPARACYP2C19CYP1A2CYP3A4MEN1 | |
| SCHEMBL9320807 | 0.80 | PPARA (0.89) | PPARACYP2C19CYP1A2CYP3A4MEN1 | |
| SCHEMBL22209208 | 0.80 | PPARG (0.74) | PPARACYP2C19CYP1A2CYP3A4MEN1 | |
| SCHEMBL4040746 | 0.76 | PPARG (0.55) | PPARACYP2C19CYP1A2CYP3A4MEN1 | |
| SCHEMBL3374117 | 0.75 | PPARA (0.64) | PPARACYP2C19CYP1A2CYP3A4MEN1 | |
| SCHEMBL4522006 | 0.75 | PPARD (0.65) | PPARAPPARDPPARGLMNAL3MBTL1 | |
| Clofibric Acid SCHEMBL102826 | 0.75 | PPARA (1.00) | PPARACYP2C19CYP1A2CYP3A4MEN1 | |
| Clofibric Acid SCHEMBL2227936 | 0.75 | PPARA (1.00) | PPARACYP2C19CYP1A2CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608639-B2 | Phenoxyether derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | claimed |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | claimed |
| US-7608639-B2 | Phenoxyether derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608639-B2 | Phenoxyether derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608639-B2 | Phenoxyether derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | disclosed |
| EP-1675814-A1 | PHENOXYETHER DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005037763-A1 | PHENOXYETHER DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | PPARA, PPARG, PPARD | PPARA 1/4885CYP2C19 619/4885CYP1A2 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.